New Zealand expands HIV prevention access regardless of visa status

On December 1, 2026—World AIDS Day—New Zealand will remove one of the last formal barriers between people and HIV prevention. Starting that day, anyone living in the country who meets clinical risk criteria will be able to access publicly funded pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), regardless of their visa status or immigration category. The change, enabled by The Healthy Futures (Pae Ora) (Eligibility) Regulations 2026, marks a shift from eligibility based on paperwork to eligibility based on actual medical need.

Until now, access to these prevention medicines has been tied to immigration status—a requirement that advocates have long argued makes no epidemiological sense. Viruses, as the saying goes, do not check passports. The new regulations align New Zealand's approach with evidence showing that HIV prevention tools work best when they reach the people most at risk, regardless of where those people come from or how long they plan to stay. The change also covers the lab testing required to prescribe and monitor treatment, meaning the full clinical pathway is now open to anyone who needs it.

Liz Gibbs, CEO of Burnett Foundation Aotearoa, framed the decision as both practical and overdue. She noted that the foundation has spent years advocating for the removal of such barriers, and that this particular change addresses a longstanding inconsistency in how New Zealand approached public health. The timing—implementation on World AIDS Day—carries symbolic weight: it signals alignment with the country's stated goal of achieving zero locally acquired HIV transmissions by 2030, a target that cannot be met if prevention tools remain out of reach for entire populations.

The evidence supporting this move is substantial. International experience and research consistently show that making HIV prevention widely available is among the most effective ways to reduce new infections. PrEP, in particular, is one of the most potent prevention tools available when taken as prescribed. Expanding access based on clinical risk rather than immigration status improves equity and removes a preventable barrier to health care. For a country with mobile populations and deep ties to the wider Pacific region, this approach also makes practical sense: people move, travel, and live across borders, and a prevention system that accounts for that reality is a more resilient one.

Yet Gibbs and the foundation were careful not to declare the work finished. Removing the visa-status barrier is important, but other obstacles remain. Access to a regular GP is not universal, particularly in rural areas. Stigma in small communities can deter people from seeking care. Wait times for appointments can stretch weeks or months, and some people face long distances to reach a clinic. The foundation has called for the next step: enabling pharmacists to supply PrEP under appropriate clinical arrangements. This would bypass some of the gatekeeping that currently exists, making prevention faster and easier to access for people without a regular doctor, those who fear judgment in their community, or those facing geographic barriers.

The regulation change itself is straightforward in its mechanics: clinical criteria replace immigration criteria as the basis for eligibility. But its implications are broader. It reflects a public health system willing to follow evidence rather than administrative convenience, and it acknowledges that prevention works best when it meets people where they are. Burnett Foundation Aotearoa will continue working with Health New Zealand and primary care providers to translate the new regulations into actual access—to ensure that the policy change becomes a lived reality for the people it is meant to protect. The next phase of work is already clear: removing the remaining barriers that stand between people and the tools that could save their lives.